

NICE Technology Appraisals: Formulary Adherence Checklist

NICE technology appraisals (TAs) are published on the fourth Wednesday of each month, except for December when it is published earlier

Produced by Medicines Information, Pharmacy,
Sunderland Royal Hospital

Dec-17

| Technology appraisal (TA) Titles are hyperlinks to full guidance | | Availability of medicine for NHS patients with this medical condition, as indicated by NICE | Adherence of local formulary to NICE | | | | | | | |
|---|--|---|--------------------------------------|---------------------------------|------------|--------------------------------------|-------------------------|---|--|-----------------|
| | | | Yes (mark 'x' if applicable) | N/A (mark 'x' if applicable) | Published | Date of local decision (DD/MM/YY) | Final Date to Implement | Time to implement as requested by NICE (days) | Time taken to implement in Sunderland (days) | Notes |
| 2017-18 | | | | | | | | | | |
| TA496 | Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | Ribociclib, with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults. | X | | 20/12/2018 | | 20/03/2019 | 90 | 42 | |
| TA495 | Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | Palbociclib, with an aromatase inhibitor, is recommended as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults. | X | | 20/12/2017 | | 20/03/2018 | 90 | 42 | |
| TA494 | Naltrexone–bupropion for managing overweight and obesity | Naltrexone–bupropion is not recommended within its marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity. | X | | 12/12/2017 | | 12/03/2018 | 90 | 50 | Not Recommended |
| TA493 | Cladribine tablets for treating relapsing–remitting multiple sclerosis | Cladribine tablets are recommended as an option for treating highly active multiple sclerosis in adults only if NICE criteria are met | X | | 06/12/2017 | | 06/03/2018 | 90 | 56 | |
| TA492 | Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable | Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed. | X | | 06/12/2017 | | 06/03/2018 | 90 | 56 | CDF |
| TA491 | Ibrutinib for treating Waldenstrom's macroglobulinaemia | Ibrutinib is recommended for use in the Cancer Drugs Fund as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 prior therapy, only if the conditions in the managed access agreement for ibrutinib are followed. | X | | 22/11/2017 | | 20/02/2018 | 90 | 70 | CDF |

| | | | | | | | | | | |
|---|---|--|---------|---------|------------|--|------------|----|--------------------------------------|--------------------------------------|
| TA490 | Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy | Nivolumab is recommended for use within the Cancer Drugs Fund as an option for treating squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if NICE criteria are met. | X | | 22/11/2017 | | 20/02/2018 | 90 | 70 | Already listed in the Formulary; CDF |
| TA489 | Vismodegib for treating basal cell carcinoma | Vismodegib is not recommended for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy, in adults. | X | | 22/11/2017 | | 20/02/2018 | 90 | 70 | Not Recommended |
| TA488 | Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | Regorafenib is recommended as an option for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib only if NICE criteria are met. | X | | 15/11/2017 | | 13/02/2018 | 90 | 77 | |
| TA487 | Venetoclax for treating chronic lymphocytic leukaemia | Venetoclax is recommended for use within the Cancer Drugs Fund as an option for treating chronic lymphocytic leukaemia, that is, in adults according to NICE criteria. | X | | 08/11/2017 | | 06/02/2018 | 90 | 85 | Already listed in the Formulary; CDF |
| 10 | | | 10 | 0 | | | | | | |
| | | | % "Yes" | % "N/A" | | | | | Average implement time (days) | |
| Adherence statistics for 2017-18 | | | 100% | 0% | | | | | 62 | |